New [1,2,4]triazolo[4,3-c]quinazoline enhances cisplatin- and temozolomide-induced growth inhibition and apoptosis in HL-60 cells
Abstract:
The purpose of this study was to investigate the therapeutic potential of a newly synthesized [1,2,4]triazolo[4,3- c]quinazoline (NTCHMTQ) alone and in combination with two anticancer drugs (cisplatin and temozolomide) against HL- 60 leukemia cell line. The IC50 value of NTCHMTQ toward HL-60 cells was 19.7 μM. No apoptosis and cell cycle changes were observed in cells treated with 5 μM NTCHMTQ alone. Combination of non-toxic concentrations of NTCHMTQ (1 – 5 μM) with cisplatin or temozolomide sensitized HL-60 cells to these two drugs and significantly enhanced their efficacies, that is illustrated by combination indexes, sub-G0 cell fraction, apoptotic DNA fragmentation and caspase-3 activity. The results suggest that combined therapy of non-toxic concentrations of NTCHMTQ with chemotherapeutics may provide synergistic regimen for treatment of leukemia. However, further in vitro and in vivo experimental drug-cell and drug-drug studies are warranted.